Cargando…

Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study

BACKGROUND: Activation of oncogenes downstream the EGFR gene contributes to colorectal tumorigenesis and determines the sensitivity to anti-EGFR treatments. The aim of this study was to evaluate the prognostic value of KRAS, BRAF, NRAS and PIK3CA mutations in a large collection of CRC patients from...

Descripción completa

Detalles Bibliográficos
Autores principales: Palomba, Grazia, Doneddu, Valentina, Cossu, Antonio, Paliogiannis, Panagiotis, Manca, Antonella, Casula, Milena, Colombino, Maria, Lanzillo, Annamaria, Defraia, Efisio, Pazzola, Antonio, Sanna, Giovanni, Putzu, Carlo, Ortu, Salvatore, Scartozzi, Mario, Ionta, Maria Teresa, Baldino, Giovanni, Sarobba, Giuseppina, Capelli, Francesca, Sedda, Tito, Virdis, Luciano, Barca, Michela, Gramignano, Giulia, Budroni, Mario, Tanda, Francesco, Palmieri, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064898/
https://www.ncbi.nlm.nih.gov/pubmed/27737711
http://dx.doi.org/10.1186/s12967-016-1053-z
_version_ 1782460240657121280
author Palomba, Grazia
Doneddu, Valentina
Cossu, Antonio
Paliogiannis, Panagiotis
Manca, Antonella
Casula, Milena
Colombino, Maria
Lanzillo, Annamaria
Defraia, Efisio
Pazzola, Antonio
Sanna, Giovanni
Putzu, Carlo
Ortu, Salvatore
Scartozzi, Mario
Ionta, Maria Teresa
Baldino, Giovanni
Sarobba, Giuseppina
Capelli, Francesca
Sedda, Tito
Virdis, Luciano
Barca, Michela
Gramignano, Giulia
Budroni, Mario
Tanda, Francesco
Palmieri, Giuseppe
author_facet Palomba, Grazia
Doneddu, Valentina
Cossu, Antonio
Paliogiannis, Panagiotis
Manca, Antonella
Casula, Milena
Colombino, Maria
Lanzillo, Annamaria
Defraia, Efisio
Pazzola, Antonio
Sanna, Giovanni
Putzu, Carlo
Ortu, Salvatore
Scartozzi, Mario
Ionta, Maria Teresa
Baldino, Giovanni
Sarobba, Giuseppina
Capelli, Francesca
Sedda, Tito
Virdis, Luciano
Barca, Michela
Gramignano, Giulia
Budroni, Mario
Tanda, Francesco
Palmieri, Giuseppe
author_sort Palomba, Grazia
collection PubMed
description BACKGROUND: Activation of oncogenes downstream the EGFR gene contributes to colorectal tumorigenesis and determines the sensitivity to anti-EGFR treatments. The aim of this study was to evaluate the prognostic value of KRAS, BRAF, NRAS and PIK3CA mutations in a large collection of CRC patients from genetically-homogeneous Sardinian population. METHODS: A total of 1284 Sardinian patients with histologically-proven diagnosis of colorectal carcinoma (CRC) and presenting with metastatic disease were included into the study. Genomic DNA was isolated from formalin-fixed, paraffin-embedded primary tumour tissue samples of CRC patients and screened for mutations in RAS and BRAF genes, using pyrosequencing assays, and in PIK3CA gene, using automated DNA sequencing assays. RESULTS: Overall, mutation rates were 35.6 % for KRAS, 4.1 % for NRAS, and 2.1 % for BRAF. Among available DNA samples, 114/796 (14.3 %) primary CRCs were found to carry a mutation in the PIK3CA gene. In this subset of patients analysed in all four genes, a pathogenetic mutation of at least one gene was discovered in about half (378/796; 47.5 %) of CRC cases. A mutated BRAF gene was found to steadily act as a negative prognostic factor for either time to progression as metastatic disease (from detection of primary CRC to diagnosis of first distant metastasis; p = 0.009) or partial survival (from diagnosis of advanced disease to the time of death or last control; p = 0.006) or overall survival (p < 0.001). No significant impact on prognosis was observed for mutated KRAS, NRAS, and PIK3CA genes or combined RAS mutations (all RAS). CONCLUSIONS: Our study defines both prevalence and prognostic role of main activated oncogenes in a population-based large collection of CRC patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-1053-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5064898
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-50648982016-10-18 Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study Palomba, Grazia Doneddu, Valentina Cossu, Antonio Paliogiannis, Panagiotis Manca, Antonella Casula, Milena Colombino, Maria Lanzillo, Annamaria Defraia, Efisio Pazzola, Antonio Sanna, Giovanni Putzu, Carlo Ortu, Salvatore Scartozzi, Mario Ionta, Maria Teresa Baldino, Giovanni Sarobba, Giuseppina Capelli, Francesca Sedda, Tito Virdis, Luciano Barca, Michela Gramignano, Giulia Budroni, Mario Tanda, Francesco Palmieri, Giuseppe J Transl Med Research BACKGROUND: Activation of oncogenes downstream the EGFR gene contributes to colorectal tumorigenesis and determines the sensitivity to anti-EGFR treatments. The aim of this study was to evaluate the prognostic value of KRAS, BRAF, NRAS and PIK3CA mutations in a large collection of CRC patients from genetically-homogeneous Sardinian population. METHODS: A total of 1284 Sardinian patients with histologically-proven diagnosis of colorectal carcinoma (CRC) and presenting with metastatic disease were included into the study. Genomic DNA was isolated from formalin-fixed, paraffin-embedded primary tumour tissue samples of CRC patients and screened for mutations in RAS and BRAF genes, using pyrosequencing assays, and in PIK3CA gene, using automated DNA sequencing assays. RESULTS: Overall, mutation rates were 35.6 % for KRAS, 4.1 % for NRAS, and 2.1 % for BRAF. Among available DNA samples, 114/796 (14.3 %) primary CRCs were found to carry a mutation in the PIK3CA gene. In this subset of patients analysed in all four genes, a pathogenetic mutation of at least one gene was discovered in about half (378/796; 47.5 %) of CRC cases. A mutated BRAF gene was found to steadily act as a negative prognostic factor for either time to progression as metastatic disease (from detection of primary CRC to diagnosis of first distant metastasis; p = 0.009) or partial survival (from diagnosis of advanced disease to the time of death or last control; p = 0.006) or overall survival (p < 0.001). No significant impact on prognosis was observed for mutated KRAS, NRAS, and PIK3CA genes or combined RAS mutations (all RAS). CONCLUSIONS: Our study defines both prevalence and prognostic role of main activated oncogenes in a population-based large collection of CRC patients. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12967-016-1053-z) contains supplementary material, which is available to authorized users. BioMed Central 2016-10-13 /pmc/articles/PMC5064898/ /pubmed/27737711 http://dx.doi.org/10.1186/s12967-016-1053-z Text en © The Author(s) 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Palomba, Grazia
Doneddu, Valentina
Cossu, Antonio
Paliogiannis, Panagiotis
Manca, Antonella
Casula, Milena
Colombino, Maria
Lanzillo, Annamaria
Defraia, Efisio
Pazzola, Antonio
Sanna, Giovanni
Putzu, Carlo
Ortu, Salvatore
Scartozzi, Mario
Ionta, Maria Teresa
Baldino, Giovanni
Sarobba, Giuseppina
Capelli, Francesca
Sedda, Tito
Virdis, Luciano
Barca, Michela
Gramignano, Giulia
Budroni, Mario
Tanda, Francesco
Palmieri, Giuseppe
Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
title Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
title_full Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
title_fullStr Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
title_full_unstemmed Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
title_short Prognostic impact of KRAS, NRAS, BRAF, and PIK3CA mutations in primary colorectal carcinomas: a population-based study
title_sort prognostic impact of kras, nras, braf, and pik3ca mutations in primary colorectal carcinomas: a population-based study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064898/
https://www.ncbi.nlm.nih.gov/pubmed/27737711
http://dx.doi.org/10.1186/s12967-016-1053-z
work_keys_str_mv AT palombagrazia prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT donedduvalentina prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT cossuantonio prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT paliogiannispanagiotis prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT mancaantonella prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT casulamilena prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT colombinomaria prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT lanzilloannamaria prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT defraiaefisio prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT pazzolaantonio prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT sannagiovanni prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT putzucarlo prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT ortusalvatore prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT scartozzimario prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT iontamariateresa prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT baldinogiovanni prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT sarobbagiuseppina prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT capellifrancesca prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT seddatito prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT virdisluciano prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT barcamichela prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT gramignanogiulia prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT budronimario prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT tandafrancesco prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy
AT palmierigiuseppe prognosticimpactofkrasnrasbrafandpik3camutationsinprimarycolorectalcarcinomasapopulationbasedstudy